You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.
In a filing with the US Securities and Exchange Commission this week, Precipio said it had amended and restated an earlier securities purchase agreement with investors.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Genome Research this week: a physical and genetic map of Cannabis sativa, evaluation of family- and population-based imputation tools, and more.
With a DNA methylation atlas and deconvolution algorithm, researchers are attempting to trace cfDNA back to tissue sources in healthy or ill individuals.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.
The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.
In an opinion piece at the Guardian, the National History Museum's Michael Dixon says the removal of Darwin and evolution from school curriculum is worrisome.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.